CN1678297A - 治疗骨关节炎的方法 - Google Patents

治疗骨关节炎的方法 Download PDF

Info

Publication number
CN1678297A
CN1678297A CNA038199513A CN03819951A CN1678297A CN 1678297 A CN1678297 A CN 1678297A CN A038199513 A CNA038199513 A CN A038199513A CN 03819951 A CN03819951 A CN 03819951A CN 1678297 A CN1678297 A CN 1678297A
Authority
CN
China
Prior art keywords
dimethyl
methyl
pain
replacement
carboxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038199513A
Other languages
English (en)
Chinese (zh)
Inventor
约瑟夫·A·科尼塞利
肯尼思·S·基尔戈
德拉戈·R·斯利斯科维克
苏珊·E·博夫
戴维·H·奈德弗
马克·C·科瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1678297A publication Critical patent/CN1678297A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038199513A 2002-08-22 2003-08-13 治疗骨关节炎的方法 Pending CN1678297A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40525002P 2002-08-22 2002-08-22
US60/405,250 2002-08-22

Publications (1)

Publication Number Publication Date
CN1678297A true CN1678297A (zh) 2005-10-05

Family

ID=31946834

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038199513A Pending CN1678297A (zh) 2002-08-22 2003-08-13 治疗骨关节炎的方法

Country Status (13)

Country Link
EP (1) EP1539127A1 (https=)
JP (1) JP2006501238A (https=)
KR (1) KR20050058454A (https=)
CN (1) CN1678297A (https=)
AU (1) AU2003255937A1 (https=)
BR (1) BR0313883A (https=)
CA (1) CA2494544A1 (https=)
IL (1) IL166600A0 (https=)
MX (1) MXPA05001254A (https=)
PL (1) PL375742A1 (https=)
TW (1) TW200410677A (https=)
WO (1) WO2004017952A1 (https=)
ZA (1) ZA200501133B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106983857A (zh) * 2008-12-16 2017-07-28 高雄医学大学 早期骨关节炎的治疗
CN113396138A (zh) * 2018-10-18 2021-09-14 燿石治疗公司 吉卡宾、其药学上可接受的盐、其组合物和其使用方法
CN118750511A (zh) * 2024-06-24 2024-10-11 中南大学湘雅医院 多元酸镁盐及其水合物在制备治疗或/和减缓关节疼痛的药物中的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105801A1 (en) * 2003-05-30 2004-12-09 Warner-Lambert Company Llc Animal model for the alleviation of pain using il-6
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
DE102008000237A1 (de) 2007-02-06 2008-08-07 Basf Se Phenol-Imidazolderivate zur Stabilisierung von polymerisationsfähigen Verbindungen
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
TWI382841B (zh) 2010-10-29 2013-01-21 Univ China Medical 用於抑制發炎之醫藥組合物
CA3059073A1 (en) * 2017-04-18 2018-10-25 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
CN114847223B (zh) * 2022-02-19 2023-11-07 昆明理工大学 一种建立oa食蟹猴模型的方法
US12208085B2 (en) * 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
SK10622002A3 (sk) * 2000-01-25 2003-07-01 Warner-Lambert Company Étery dikarboxylátu vápenatého, metódy ich výroby a ich využitie na liečbu vaskulárnych chorôb a diabetu
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106983857A (zh) * 2008-12-16 2017-07-28 高雄医学大学 早期骨关节炎的治疗
CN113396138A (zh) * 2018-10-18 2021-09-14 燿石治疗公司 吉卡宾、其药学上可接受的盐、其组合物和其使用方法
CN118750511A (zh) * 2024-06-24 2024-10-11 中南大学湘雅医院 多元酸镁盐及其水合物在制备治疗或/和减缓关节疼痛的药物中的用途

Also Published As

Publication number Publication date
IL166600A0 (en) 2006-01-15
TW200410677A (en) 2004-07-01
CA2494544A1 (en) 2004-03-04
MXPA05001254A (es) 2005-06-08
BR0313883A (pt) 2005-07-19
WO2004017952A1 (en) 2004-03-04
KR20050058454A (ko) 2005-06-16
PL375742A1 (en) 2005-12-12
ZA200501133B (en) 2008-01-30
AU2003255937A1 (en) 2004-03-11
JP2006501238A (ja) 2006-01-12
EP1539127A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
CN1250526C (zh) 吡咯取代的2－吲哚满酮蛋白激酶抑制剂
CN1299683C (zh) 塞内昔布组合物
CN100343255C (zh) 吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
CN1149204C (zh) 1-杂环取代的二芳基胺
CN1229142C (zh) 用于治疗或抑制结肠息肉和结肠直肠癌的含有nsaid和efgr激酶抑制剂的组合物
CN1284944A (zh) 整联蛋白受体拮抗剂
CN1678297A (zh) 治疗骨关节炎的方法
CN1711089A (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
CN1523982A (zh) 减少体脂和调节脂肪酸代谢的方法、化合物和组合物
CN1829804A (zh) 治疗认知功能障碍的靶位
CN1355790A (zh) 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
CN1154496C (zh) 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
CN1617729A (zh) 具有胆汁酸输送抑制活性的苯并噻氮䓬类在降低胆固醇血症中的应用
CN1356872A (zh) 调节蛋白激酶活性和用于癌症化疗的3－亚杂芳基－2－吲哚满酮化合物
CN1939307A (zh) 2,4,6－三氨基－1,3,5－三嗪衍生物
CN1279617A (zh) 醛糖还原酶抑制剂和糖原磷酸化酶抑制剂的组合物
CN1290165A (zh) 苯并噻唑蛋白酪氨酸激酶抑制剂
CN1142492A (zh) 用作抗糖尿病剂的取代n-(吲哚-2-羰基)甘氨酰胺及其衍生物
CN1237960A (zh) N(－芳基/杂芳基乙酰基)氨基酸酯、包括这些酯的药用组合物以及用这些化合物抑制β淀粉样肽释放和/或合成的方法
CN1113436A (zh) 药物反应的增效作用
CN1627944A (zh) 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
CN1543453A (zh) 作为纤溶酶原激活物抑制剂1型(pai-1)的6-(芳基-酰氨基或芳基-酰氨甲基)-萘-2-基氧基-酸衍生物
CN1660840A (zh) 治疗炎性疾病的酞嗪衍生物
CN101080411A (zh) 作为mch受体拮抗剂的噻唑并吡啶酮衍生物
CN1238689A (zh) 玻连蛋白受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication